BioNTech SE (NASDAQ:BNTX) Stock Position Lowered by Van ECK Associates Corp

Van ECK Associates Corp trimmed its position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 13.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 108,696 shares of the company's stock after selling 17,318 shares during the period. Van ECK Associates Corp's holdings in BioNTech were worth $11,472,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Baillie Gifford & Co. increased its holdings in BioNTech by 15.5% in the third quarter. Baillie Gifford & Co. now owns 8,602,839 shares of the company's stock valued at $934,612,000 after buying an additional 1,152,541 shares during the last quarter. Clearbridge Investments LLC lifted its position in shares of BioNTech by 41.6% during the 3rd quarter. Clearbridge Investments LLC now owns 484,126 shares of the company's stock worth $52,595,000 after buying an additional 142,344 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in shares of BioNTech by 43.1% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 425,071 shares of the company's stock valued at $44,610,000 after buying an additional 127,951 shares in the last quarter. abrdn plc acquired a new stake in BioNTech during the 4th quarter worth $10,961,000. Finally, Bamco Inc. NY lifted its position in BioNTech by 123.1% in the third quarter. Bamco Inc. NY now owns 158,911 shares of the company's stock valued at $17,264,000 after acquiring an additional 87,686 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Price Performance

Shares of BNTX traded up $0.48 during mid-day trading on Friday, hitting $92.72. The company's stock had a trading volume of 661,736 shares, compared to its average volume of 654,446. The firm has a 50-day simple moving average of $90.56 and a 200 day simple moving average of $96.01. BioNTech SE has a 1-year low of $85.21 and a 1-year high of $125.83. The firm has a market capitalization of $22.04 billion, a P/E ratio of 22.39 and a beta of 0.25. The company has a current ratio of 9.43, a quick ratio of 9.26 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its earnings results on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing the consensus estimate of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The company had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $2.04 billion. Analysts predict that BioNTech SE will post -1.74 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on BNTX. BMO Capital Markets reduced their target price on BioNTech from $127.00 to $123.00 and set an "outperform" rating for the company in a report on Thursday, March 21st. The Goldman Sachs Group lowered their target price on shares of BioNTech from $113.00 to $100.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 28th. UBS Group reduced their price target on shares of BioNTech from $110.00 to $101.00 and set a "neutral" rating for the company in a research report on Wednesday, March 27th. HC Wainwright reissued a "buy" rating and set a $107.00 price objective on shares of BioNTech in a research report on Wednesday, April 17th. Finally, Canaccord Genuity Group restated a "buy" rating and issued a $171.00 price objective on shares of BioNTech in a research note on Thursday, March 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $120.40.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.